Quarterly report [Sections 13 or 15(d)]

Balance Sheet Components

v3.26.1
Balance Sheet Components
 6 Months Ended
Jun. 30, 2026
Balance Sheet Components [Abstract]  
Balance Sheet Components

5. Balance Sheet Components

 

Prepaid expenses and other current assets as of December 31, 2025 and June 30, 2026 consisted of the following (in thousands):

 

    As of     As of  
    December 31,     June 30,  
    2025     2026  
             
Prepaid directors’ and officers’ liability insurance premiums   $ 332     $ 24  
Prepaid drug manufacturing supply costs     6,189       7,601  
Other     1,171       2,270  
Total   $     7,692     $ 9,895  

 

Property and equipment as of December 31, 2025 and June 30, 2026 consisted of the following (in thousands):

 

    As of     As of  
    December 31,     June 30,  
    2025     2026  
             
Leasehold improvements   $ 65     $ 36  
Lab equipment     26       26  
Furniture and fixtures     47       44  
Subtotal     138       106  
Less accumulated depreciation     (72 )     (65 )
Net   $ 66     $ 41  

 

Depreciation expense was immaterial for the six months ended June 30, 2026 and 2025 and is included in general and administrative expenses.

 

Accounts payable as of December 31, 2025 and June 30, 2026 consisted of the following (in thousands):

 

    As of     As of  
    December 31,     June 30,  
    2025     2026  
             
Trade accounts payable   $ 301     $ 2,167  
Credit card liability     82       67  
Total   $ 383     $ 2,234  

 

Accrued liabilities as of December 31, 2025 and June 30, 2026 consisted of the following (in thousands):

 

    As of     As of  
    December 31,     June 30,  
    2025     2026  
             
Accrued labor costs   $ 329     $ 1,000  
Accrued drug development costs     753       615  
Other     441       521  
Total   $     1,523     $ 2,136